News
NUTRILEADS closes series a round to advance the development of its lead nutritional ingredient supporting immune function
Dutch nutritional health ingredients startup NUTRILEADS B.V. today announces the successful closing of a Series A financing round with existing shareholders DSM VENTURING, PPM OOST, SHIFT INVEST and THUJA CAPITAL.
NutriLeads develops supportive nutritional ingredients for application in dietary
supplements, medical food and functional food products intended for specific target
populations seeking to support their immune function. Its lead ingredient aims to
support immune function and increase resistance to common infectious diseases
such as colds and flu.
A proof of concept study in human volunteers showed an excellent tolerability and
safety profile. More importantly, a dose dependent effect regarding the enhancement
of immune function was demonstrated. In addition to these positive clinical results, a
recent production pilot showed the feasibility of a cost-effective and sustainable
production process for its lead ingredient.
The current Series A financing will be used to support the further development of
NutriLead’s lead ingredient, a novel Immune Modulating Plant Polysaccharide.
During the next phase, production will be scaled up and two human clinical trials to
substantiate the immune supportive effect in different target populations will be
performed.
“The current investment supports the fast track development of our lead ingredient for application in dietary supplements, medical foods and functional foods. We are
confident that this will help us realize our ambition to partner with ingredient suppliers and food companies to bring the benefits of our health ingredients to patients and consumers” indicates Ruud Albers, PhD, CEO of NutriLeads.